Summit Financial’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$26.1M Buy
28,323
+13,074
+86% +$13.3M 0.33% 58
2025
Q4
$16.4M Buy
15,249
+372
+3% +$356K 0.24% 78
2025
Q3
$11.4M Buy
14,877
+815
+6% +$606K 0.17% 110
2025
Q2
$11M Buy
14,062
+1,574
+13% +$1.22M 0.25% 70
2025
Q1
$10.3M Buy
12,488
+20
+0.2% +$16.6K 0.29% 66
2024
Q4
$9.63M Buy
12,468
+5,984
+92% +$4.95M 0.34% 52
2024
Q3
$5.74M Sell
6,484
-1,890
-23% -$1.7M 0.23% 78
2024
Q2
$7.58M Buy
8,374
+5,939
+244% +$4.75M 0.35% 46
2024
Q1
$1.89M Sell
2,435
-345
-12% -$246K 0.11% 107
2023
Q4
$1.62M Sell
2,780
-176
-6% -$103K 0.11% 120
2023
Q3
$1.59M Sell
2,956
-7,516
-72% -$3.87M 0.12% 115
2023
Q2
$4.91M Buy
10,472
+6,982
+200% +$2.93M 0.36% 40
2023
Q1
$1.2M Buy
3,490
+926
+36% +$312K 0.1% 101
2022
Q4
$938K Buy
2,564
+228
+10% +$80.8K 0.09% 119
2022
Q3
$755K Buy
2,336
+1,270
+119% +$402K 0.07% 133
2022
Q2
$346K Sell
1,066
-12
-1% -$3.6K 0.03% 187
2022
Q1
$309K Buy
1,078
+1
+0.1% +$257 0.02% 217
2021
Q4
$297K Buy
+1,077
New +$273K 0.02% 213

Other funds holding LLY

Summit Financial's LLY Position: Q1 2026 in Review

Summit Financial increased its Eli Lilly (LLY) stake by 86% in Q1 2026, buying an estimated $13.3M and bringing the position to 28,323 shares worth $26.1M. The position accounts for 0.33% of the portfolio, ranked #58.

Summit Financial first reported a position in LLY in Q4 2021 and has held it in 18 quarters since. 4,355 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Summit Financial held 28,323 shares of Eli Lilly worth $26.1M as of Q1 2026.
  • Summit Financial bought 13,074 Eli Lilly shares in Q1 2026, an estimated $13.3M.
  • Eli Lilly made up 0.33% of Summit Financial's portfolio in Q1 2026, its #58 holding.
  • Summit Financial first reported a position in Eli Lilly in Q4 2021 and has held it in 18 quarters since.
  • 4,355 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Summit Financial's 13F filing for Q1 2026, filed 15 May 2026.